|
|
InterMune, Inc. - Comparative Business Analysis Snapshot
Business Description
InterMune, Inc.. The Group's principal activity is that of biotech company focused on development and commercialization of innovative therapies in pulmonology and hepatology. It has a product portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Actimmune and Pirfenidone; Actimmune is being evaluated in the INSPIRE Trial, a Phase III and Pirfenidone in the Phase II. The hepatology portfolio includes the lead HCV protease inhibitor PEG-Alfacon-1 in the Phase I, for Chronic Hepatitis C Virus Infections to further expand the limited treatments for HCV infections. The major customers include CuraScript Inc, Caremark, Nova Factor and Merck Medco.
Competitor Analysis
This analysis compares InterMune, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
